Symbio Pharmaceuticals Limited (4582) Stock Statistics & Valuation Metrics

Symbio Pharmaceuticals Limited has a market cap or net worth of ¥5.42B. The enterprise value is ¥2.93B.

Symbio Pharmaceuticals Limited has 76,416,760 shares outstanding. The number of shares has decreased by -2.65% in one year.

Symbio Pharmaceuticals Limited’s return on equity (ROE) is -3.75 and return on invested capital (ROIC) is -136.24%.

The current PE Ratio of Symbio Pharmaceuticals Limited is ―. Symbio Pharmaceuticals Limited’s PEG ratio is -0.08.

In the last 12 months, Symbio Pharmaceuticals Limited had revenue of 1.31B and earned -4.78B in profits. Earnings per share was -95.12.

In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.

Symbio Pharmaceuticals Limited pays an annual dividend of ―, resulting in a dividend yield of ―

Symbio Pharmaceuticals Limited upcoming earnings date is Jul 30, 2026, TBA (Confirmed).

Symbio Pharmaceuticals Limited as a current ratio of 2.96, with Debt / Equity ratio of 443.48%

In the past 12 months, Symbio Pharmaceuticals Limited has paid 27.57M in taxes.

Symbio Pharmaceuticals Limited EV to EBITDA ratio is -0.79, with an EV/FCF ratio of -0.79.

Symbio Pharmaceuticals Limited has ¥3.05B in cash and marketable securities with ¥1.30B in debt, giving a net cash position of ¥1.75B billion.

Gross margin is 71.86%, with operating margin of -339.59%, and net profit margin of -365.25%.

The average price target for Symbio Pharmaceuticals Limited is ―, which is 11.43% higher than the current price. The consensus rating is ―